Skip to main content

letter

. 1996 Nov 30;313(7069):1400. doi: 10.1136/bmj.313.7069.1400

Intravenous immunoglobulin in the Guillain-Barré syndrome. Products with low IgA content may be used in patients with total IgA deficiency.

PMCID: PMC2352877 PMID: 8956720

1400

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Buckley R. H., Schiff R. I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991 Jul 11;325(2):110–117. doi: 10.1056/NEJM199107113250207. [DOI] [PubMed] [Google Scholar]
Cunningham-Rundles C., Zhou Z., Mankarious S., Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol. 1993 Jul;13(4):272–278. doi: 10.1007/BF00919386. [DOI] [PubMed] [Google Scholar]
Hughes R. A. Intravenous IgG in Guillain-Barré syndrome. BMJ. 1996 Aug 17;313(7054):376–377. doi: 10.1136/bmj.313.7054.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tan E., Hajinazarian M., Bay W., Neff J., Mendell J. R. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993 Feb;50(2):137–139. doi: 10.1001/archneur.1993.00540020015010. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES